K 01-162 (K162) inhibits the fibril formation of A β peptides and eliminates their neurotoxicity. K 01-162 binds with A β 42 peptide with an EC 50 value of 80 nM. K 01-162 binds directly to AβO with a K D value of 19 μM. K 01-162 is capable of penetrating the brain and can be used for the research of Alzheimer’s disease.
In Vitro
K 01-162 (1 μM; 24 h) reduces the level of intracellular AβO. K 01-162 (0.78-50 μM; 5 min) blocks the synaptic binding activity of AβO in mouse hippocampal neurons. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: MC65 cell line Concentration: 1 μM Incubation Time: 24 hours Result: Reduced the levels of SDS-stable Aβ trimer and larger aggregates.
In Vivo
K 01-162 (100 μM; intracerebroventricular infusion 0.25 μL/h for 2 weeks) attenuates amyloid load in vivo. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 5xFAD mice with cerebral Aβ amyloidosisDosage: 100 μM Administration: Intracerebroventricular infusion; 100 μM 0.25 μL/h; for 2 weeks Result: Caused no apparent toxicity and significantly reduced the amyloid load in hippocampus to\n50% of the mock-treated level.
